Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3900168 | 0.91 | — | — | |
| SCHEMBL3902708 | 0.90 | — | — | |
| SCHEMBL3900860 | 0.90 | — | — | |
| SCHEMBL3901129 | 0.80 | — | — | |
| SCHEMBL3900170 | 0.78 | — | — | |
| SCHEMBL3901111 | 0.78 | PDF (0.31) | — | |
| SCHEMBL5188809 | 0.75 | PDF (0.35) | — | |
| SCHEMBL3901599 | 0.74 | MAPT (0.40) | — | |
| SCHEMBL8014494 | 0.71 | KMT2A (0.40) | ALOX15BLMPMP22KMT2A | |
| SCHEMBL3907840 | 0.70 | PDF (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615629-B1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-03-18 | — | — | EP | claimed |
| US-7375120-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-20 | — | — | US | claimed |
| US-20060229341-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2006-10-12 | — | — | US | claimed |
| EP-1615629-B1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7375120-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1615629-A4 | PEPTIDE DEFORMYLASE INHIBITORS | CHRISTENSEN SIEGFRIED B IV (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20060229341-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2006-10-12 | — | — | US | disclosed |
| EP-1615629-A1 | PEPTIDE DEFORMYLASE INHIBITORS | Christensen, Siegfried B. IV (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004098584-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229341-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | ALOX15 3509/4885BLM 2145/4885PMP22 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.